Although these mechanisms remain to be explored, the findings of abnormally high HER2 signaling activities in a subset of HER2− tumors offer an alternative explanation for why some patients with HER2− breast cancer derive benefit from HER2 signaling inhibitors. This evidence concerns the gene ERBB2 and breast carcinoma.